Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of cabozantinib versus placebo in radioactive iodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy
MOH_2019-05-01_007110Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing Cabozantinib with Placebo (2 arms). Started Apr 2019; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on MOH_2019-05-01_007110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-01_007110.